Compare ITGR & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ITGR | ABCL |
|---|---|---|
| Founded | 1970 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 4.1B |
| IPO Year | 2000 | 2020 |
| Metric | ITGR | ABCL |
|---|---|---|
| Price | $126.70 | $11.84 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 12 |
| Target Price | ★ $121.80 | $16.82 |
| AVG Volume (30 Days) | 678.5K | ★ 5.0M |
| Earning Date | 10-30-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.91 |
| EPS | ★ 1.17 | N/A |
| Revenue | ★ $1,853,637,000.00 | $75,128,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.96 | $7.12 |
| P/E Ratio | $108.32 | ★ N/A |
| Revenue Growth | 7.98 | ★ 160.56 |
| 52 Week Low | $62.00 | $2.75 |
| 52 Week High | $126.80 | $14.98 |
| Indicator | ITGR | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 72.72 | 44.43 |
| Support Level | $126.16 | $11.78 |
| Resistance Level | $126.80 | $12.88 |
| Average True Range (ATR) | 0.13 | 0.78 |
| MACD | -0.21 | -0.26 |
| Stochastic Oscillator | 79.41 | 4.36 |
Integer Holdings Corp is a manufacturer of medical device components used by original equipment manufacturers in the medical industry. The firm organizes itself into one segment and derives its revenues from three product lines: Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation and Other Markets. The company earns maximum of its revenue in the United States, and also has its presence in Ireland, Puerto Rico, Costa Rica, and Rest of the World.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.